Ohio State Food Research Leaders Present Critical UST Process Applications, Scalability, and Cleanup
Validation results for food safety, stability and optimization of the experiment; Launch of the system in the fourth quarter of 2022
SOUTH EASTON, MA /ACCESSWIRE/September 27, 2022/ Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of large-scale pressure-based instruments, consumables and specialty test services for the global food and beverage, health and wellness, nutraceuticals, cosmetics and other industries, today highlighted two important presentations given at Food Engineering Conference 2022 by a team Distinguished Research Paper from The Ohio State University College of Food, Agricultural, and Environmental Sciences and co-authored by members of PBI’s R&D and Engineering teams. These presentations continued to reinforce the dramatic benefits of PBI’s revolutionary Ultra Shear Technology™ (UST™) platform to optimize food safety, preservation, stability and consumer sensory experience. Most importantly, they validated the unique scalability of PBI’s UST platform and its ability to meet the challenges of commercial introduction at production scales suitable to serve multi-billion dollar applications and markets.
The Conference of Food Engineering provides engineers from the food industry, academia and government with a widely respected platform to share and discuss the latest and most exciting research findings and developments affecting the food industry and drinks. Participants include leading researchers from universities across the United States, as well as Europe, Asia/Pacific, Africa and Latin America. The participation and integration of food industry research and business leaders is strongly emphasized and welcomed.
World-renowned food science innovator and OSU Professor VM (Bala) Balasubramanian provided a powerful validation of the end product benefits of UST in food processing, in a presentation titled “Principles of Ultra Shear Technology and Its application in the treatment of Clean Label drinks”. Dr. Bala and his team presented conclusive data summarizing that:
PBI’s UST platform offers significant advantages over high pressure processing (HPP) (estimated $15.5 billion market) and pasteurization by reducing harmful spoilage and pathogenic bacteria in beverages. vegetable proteins.
The UST process powerfully reduced droplet/particle size and beneficially changed other key characteristics (e.g. viscosity). An important finding has enabled the addition of plant-derived pea protein supplements to dairy products, opening new avenues for high-demand, nutritionally-enriched plant-based protein products.
The UST process opens and promises new avenues for developing new functional beverages with greatly improved nutritional, safety and economic characteristics.
The second presentation, titled “Cleaning and Sanitizing Method for Pilot-Scale UST Equipment for Liquid Food Processing,” was presented by OSU Ph.D. candidate Hetian Hu and colleagues. The objective of the study was to develop a “cleaning-in-place” (CIP) protocol for cleaning and disinfecting UST equipment from pilot scale to commercial scale and to evaluate the effectiveness of the protocol, critical issues necessary to ensure commercial success. Hu and his team concluded:
The CIP protocol reduced the microbial concentration below the detection limits for each test location point.
The developed CIP protocol effectively sanitized pilot-scale UST equipment, suitable for rapid preparation time between products.
Future users of UST equipment can benefit from this study by adapting the developed CIP protocol for use in even larger industrial-scale UST processors that are expected to become commercially available in the future.
Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed, “We are preparing to launch the first UST processed products for business partners in the coming weeks. Validation of these recent studies for commercial readiness of UST for production scale will now open the door to accelerating partnerships in countless applications spanning diverse multi-billion dollar markets, where effective solubility in l water of oil-based active ingredients is essential for optimized bioavailability and absorption – including food and beverages, nutraceuticals, cosmetics, agrochemicals and pharmaceuticals.”
Mr. Richard T. Schumacher, President and CEO of PBI, summarized, “The results of these studies presented by our colleagues at OSU provide strong and invaluable support for our impending commercial launch activities. They highlight success in achieving the two critical goals we set for ourselves prior to launch, that: (1) the UST platform can provide an effective and efficient pathway to manufacturing clean nutritional beverages with functional, economic and of durability, and (2) UST BaroShear equipment can be validated to provide the critical economic criterion of an efficient and economical CIP process that can be performed with minimal effort and in accordance with FDA guidelines for processing, food cleaning and decontamination.
Mr. Schumacher concluded, “I am delighted to say that our plans to commercially launch the UST platform through our East Coast Toll Site in Q4 2022 are now at ‘All Systems Go!'”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for global life sciences and other industries. Our products are based on the unique properties of constant hydrostatic (ie static) and alternating (ie pressure cycle technology or PCT) pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions in a safe and reproducible manner (eg, cell lysis, biomolecule extraction). Our primary focus is PCT-based product development for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics and anti-bioterrorism applications. In addition, major new market opportunities have arisen in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired patented technology from BaroFold, Inc. (the “BaroFold” technology ) to enable entry into the biopharmaceutical contract services industry, and (2) the use of our recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform for (i ) to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare high-quality, homogenized, extended shelf-life, or room-temperature stable low-acid liquid foods that cannot be efficiently preserved using existing non-thermal technologies.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements or those of our industry are materially different from the results, future levels of activity, performance or achievements expressed, implied or inferred by such forward-looking statements. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “could”, “should”, “expect”, “plan”, ” intends”, “anticipates”, “believes”, estimates”, “predicts”, “projects”, “potential” or “continues” or the negative form of these terms and other comparable terms. These statements are only predictions based on our current expectations and projections regarding future events. You should not place undue reliance on these statements. When evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statements. risks, uncertainties and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 , and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update the information contained in this press release, except as otherwise required by law.
For more information on PBI and this press release, please click on the following link:
Please visit us on Facebook, LinkedIn and Twitter.
Richard T. Schumacher, President and CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Kenneth F. Micciche Director of Business Development (508) 230-1828(T)
Jeffrey N. Peterson, Chairman (650) 703-8557 (T)
THE SOURCE: Pressure BioSciences Inc.
See the source version on accesswire.com: